- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03741712
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
February 2, 2021 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Phase I/II,Open-Label,Does-Escalation and -Expansion, Safety,Pharmacokinetics and Efficacy Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of Patients With Metastatic Castration Resistant Prostate Cancer
The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
This is a multicenter, open, non-randomized and dose-escalating and -expansion Phase I/II trial and it studies the tolerance, PK and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.
The Phase I part is a dose-escalating study including Ia (dose-escalation monotherapy) and Ib (dose-escalation combination therapy).
Approximately 18-30 patients in Phase Ia will only receive one of five dose levels of orally SHR2554.
Approximately 30~48 patients in Phase Ib trial will receive SHR2554 combined with SHR3680, in which 2~3 different dose levels of SHR2554 will be selected based on the result of the Phase Ia.
Phase II part is a dose-expansion study.
Primary endpoints of the study are dose-limiting tolerance (DLT), maximum-tolerated dose (MTD) and prostate specific antigen (PSA) response rate.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Fudan University Shanghai Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Histologically or cytologically confirmed prostate cancer;
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1;
- Radiographic evidence of metastasis;
- Sustained therapy of luteinizing hormone-releasing hormone analogue(LHRHA)or received bilateral orchiectomy; patients who did not receive bilateral orchiectomy are willing to receive sustained therapy of LHRHA;
- Evidence of prostate cancer progression under the sustained therapy of LHRHA or bilateral orchiectomy;
- Adequate hepatic, renal, heart, and hematological functions;
- Patients have given voluntary written informed consent before performance of any study-related procedure not part of normal medical care,with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
Exclusion Criteria:
- Have received any anti-tumor therapy in the past 4 weeks,including radiotherapy, chemotherapy, operation, targeted therapy, immunotherapy, and endocrinotherapy;
- Planned to initiate any other anti-tumor therapies during the study;
- Unable to swallow, chronic diarrhea and intestinal obstruction, or the presence of a variety of other factors that affect drug use and absorption;
- Clinically significant cardiovascular diseases;
- History of seizure or certain conditions that may predispose to seizure;
- Severe concurrent disease and infection that, in the judgment of the investigator, would make the patient inappropriate for enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SHR2554
Participants will receive SHR2554 orally
|
Tablet.
Specifications of 50mg and 200mg
|
EXPERIMENTAL: SHR2554+SHR3680
Participants will receive SHR2554 combined with SHR3680 orally
|
Tablet. Specifications of 80mg
Tablet.
Specifications of 50mg and 200mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DLT
Time Frame: Approximately 12 months
|
A DLT is any of the predefined set of unacceptable adverse events observed and at least possibly related to investigational agents
|
Approximately 12 months
|
MTD
Time Frame: Approximately 12 months
|
The first cycle DLTs will be utilized to determine the MTD and future dose escalations or de-escalations The first cycle DLTs will be utilized to determine the MTD and future dose escalations or de-escalations
|
Approximately 12 months
|
PSA response rate
Time Frame: Approximately 12 weeks
|
After the continuous therapy from randomisation to the end of the 12 weeks, the ratio of patients whose levels of PSA decreased more than 50%
|
Approximately 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Plasma Concentration (Cmax)
Time Frame: Approximately 12 months
|
The single-dose and multiple dose PK will be calculated as data permits including Cmax
|
Approximately 12 months
|
Objective response rate (ORR)
Time Frame: Approximately 70 months
|
The percentage of subjects with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
|
Approximately 70 months
|
Time to PSA progression
Time Frame: Approximately 70 months
|
Time from randomisation to the first time of PSA progression according to the criteria of the Prostate Cancer Clinical Trials Working Group 3 (PCWG3)
|
Approximately 70 months
|
Under the Curve (AUC)
Time Frame: Approximately 12 months
|
The single dose and multiple dose PK will be calculated as data permits including Area AUC
|
Approximately 12 months
|
Adverse events (AE)
Time Frame: Approximately 70 months
|
The type, frequency, severity, timing, seriousness, and relationship to study therapy
|
Approximately 70 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 20, 2018
Primary Completion (ACTUAL)
September 30, 2019
Study Completion (ACTUAL)
December 8, 2020
Study Registration Dates
First Submitted
October 17, 2018
First Submitted That Met QC Criteria
November 12, 2018
First Posted (ACTUAL)
November 15, 2018
Study Record Updates
Last Update Posted (ACTUAL)
February 5, 2021
Last Update Submitted That Met QC Criteria
February 2, 2021
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR2554-SHR3680-I/II-102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on SHR3680
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHormone Refractory Prostate Cancer | Metastatic Prostate CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingCastration-Resistant Prostate CancerChina
-
Atridia Pty Ltd.CompletedProstate Cancer | NeoplasmAustralia
-
Jiangsu HengRui Medicine Co., Ltd.UnknownProstate Cancer | Castration-resistant Prostate CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingHepatic Impairment | Healthy ParticipantsChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownProstate Cancer MetastaticChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingPatients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyChina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Jiangsu HengRui Medicine Co., Ltd.RecruitingProstate Cancer | Biochemical RecurrenceChina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Recruiting